Mannheim, Germany
Mannheim, Germany

Time filter

Source Type

News Article | April 17, 2017
Site: en.prnasia.com

TOKYO, April 17, 2017 /PRNewswire/ -- Reed Exhibitions Japan will be holding the 26th edition of Japan IT Week Spring from May 10-12 at Tokyo Big Sight, Japan. The show is the largest annual business platform in Japan for IT professionals, covering various sectors of IT ranging from microprocessors to the latest applications. This year 91,000 professional visitors and 1,600 exhibitors will gather across 13 exhibitions; Software & Apps Development Expo (SODEC), Big Data Management Expo (BIG DATA Spring), Embedded Systems Expo (ESEC Spring), Data Storage Expo (DSE), Data Center Expo (DATA CENTER Spring), Information Security Expo (IST Spring), Web & Digital Marketing Expo (Web-Mo Spring), Cloud Computing Expo Japan (CLOUD JAPAN Spring), Mobile Solutions Expo (MOBIX Spring), IoT/M2M EXPO (IoT/M2M Spring), Direct Commerce Solutions Expo (DIREX Spring), Consumer IT Products Expo (C-PEX) and Store & Retail IT Solutions Expo (STOREX Spring). With the need for high quality products, the latest technology and international outsourcing increasing in the Japanese IT market, exhibitors joining 26th Japan IT Week Spring from overseas have been rising. Reflecting such trend, the percentage of international firms will be 1.3 fold higher and the overall scale will be expanding by more than 10%. New Exhibition for Store & Retail IT Solutions One of the highlights of this year's show will be the newly launching exhibition - Store & Retail IT Solutions Expo (STOREX Spring) to aid business between corporate professionals and firms looking to invest in the field of store and retail IT solutions. Exhibits will include Store Operations Solutions, Omni-Channel Retailing, POS Systems, Store Sales Promotion Solutions, and Customer Service Solutions. TSUBAKIMOTO CHAIN and DATAVAN INTERNATIONAL will be showcasing their latest terminals. The launch of STOREX Spring is one of the contributing factors for the show expansion and increasing overall participation. Since STOREX Spring is concurrently held with Direct Commerce Solutions Expo (DIREX Spring) and Web & Digital Marketing Expo (Web-Mo Spring), the show is expected to gather large quantity of visitors in hospitality industry. "IoT/M2M EXPO (IoT/M2M Spring)" had been serving as the platform for various chip manufacturers, firms with exhibits related to connective technologies and applications to negotiate business at 26th Japan IT Week Spring as the concept of IoT continues to spread and emerge new business. From devices, operators, solution providers to applications related to IoT and M2M, a wide range of firms will be exhibiting such as chip manufacturers including QUALCOMM, MURATA MANUFACTURING, wireless chip manufacturers such as TOKYO ELECTRON DEVICE, HITACHI, TELIT, U-BLOX, operators such as NTT DOCOMO, VODAFONE, KDDI and solution providers including MICROSOFT, ROBERT BOSCH, SORACOM will also be exhibiting. Special Session will be delivered at the conference held parallel to the exhibition where ROBERT BOSCH, SIEMENS, QUALCOMM and FANUC will explain newly generated market values, technical developments and essential next steps will be addressed. The 3 major Japanese operators DOCOMO, SOFTBANK and KDDI will also hold Special Sessions. With the expansion of IoT/M2M EXPO (IoT/M2M Spring), Embedded Systems Expo (ESEC Spring) is also growing as supporting technologies of IoT and M2M. Major firms exhibiting from Japan include MITSUBISHI, SONY, TOSHIBA, RICOH, CANON and from overseas INTEL, ADLINK, ADVANTECH, CONGATEC, TRANSCEND, BECKHOFF AUTOMATION, PHOENIX CONTACT etc. On the topic of embedded systems, DeNA and an expert from the UNIVERSITY OF TOKYO will be holding talks on autonomous driving technologies at the Keynote Session. With the rise in identity fraud, unauthorized access and cyber-attacks in Japan, information security is a major area of interest. The trending concept of IoT also inevitably addresses the need to direct attention towards security issues for connectivity. Major firms exhibiting include TREND MICRO, IBM, DOCOMO SYSTEMS, HITACHI SOLUTIONS, CANON IT SOLUTIONS, NTT SOFTWARE, KYOCERA, CYLANCE etc. will be showcasing various exhibits such as hacking preventions, DoS preventions, anti-virus solutions, internet intrusion protections, data delete/recovery, IT asset management products and services. At the Keynote for Information Security Expo (IST Spring), TREND MICRO will hold a talk on the current status and future of ICT security and SYMANTEC will speak on Cyber security of the Rio Olympic Games as an official security sponsor. MICROSOFT will also be discussing the role and responsibility of IT department inside firms regarding security strategies. To search for exhibitors and exhibit information: www.japan-it.jp/en/haru/eguide/ 26th Japan IT Week is Japan's largest trade show with established presence in Japanese IT industry and the show has been growing consistently attracting more and more IT professionals around the world. This year, the show is expecting to welcome 350 international exhibitors from 21 different countries with several national pavilions. The show truly serves as the best platform to connect with the latest IT solutions from all over the world. In addition to the must-see exhibition, 26th Japan IT Week Spring holds a total of 56 conference sessions conducted by globally renowned speakers in the industry such as IBM, MICROSOFT and QUALCOMM covering wide range of the latest topics. For details of the conference: www.japan-it.jp/en/Conference/Conference-Program/   Full program in Japanese: www.japan-it.jp/haru/seminar/ 26th Japan IT Week Spring is inarguably a must-attend show that provides solutions for all global IT experts. Free visitor registration can be made online for free at: www.japan-it.jp/en/haru/inv/ For IT professionals with job titles above manager, VIP visitor registrations with privileges can be made online at: www.japan-it.jp/en/haru/vip/ For more information about 26th Japan IT Week Spring, visit the official website: www.japan-it.jp/en/haru/


MELVILLE, N.Y.--(BUSINESS WIRE)--Verint® Systems Inc. (Nasdaq: VRNT) today announced its participation in various speaking engagements and industry events taking place this month. CX Sydney 2017 May 9; Sydney, Australia Martyn Riddle, APAC marketing director, will serve as a panelist during the “Customer-Obsessed Game Changers” session at 2:50 pm AEST. Attendees of this Forrester event will hear from a group of digital customer experience (CX) leaders about how traditional enterprises can challenge conventional notions of commerce and CX; how cultures and organizations need to adapt to the digital economy; and how marketers and technologists need to collaborate to define brands and delight customers. Korea Channel & Communication Management Conference May 17; Seoul, South Korea Craig Seebach, VP, enterprise workforce optimization, will take part in the session “Creating a Customer Engagement Culture by Focusing on Workforce Optimization and Employee Engagement” at 10:40 am KST. Attendees will learn how WFO and employee engagement solutions are directly impacting both customer experiences and loyalty. CXPA Insight Exchange 2017 May 16-17; Phoenix, Arizona Raj Sivasubramanian, director, customer experience services, will present “Is Your Omnichannel Strategy Customer-Centric or Self-Centric?” on May 17 at 11 am ET. Many organizations have invested significant resources and time in omnichannel strategies. This session will explore how these strategies can equally benefit both companies and their customers and the role seamless communications across online and offline channels plays. Verint Engage: Global Customer Conference 2017 May 22-25; Orlando, Florida Customers from around the world will convene for this annual event that highlights customer success, market trends, technology innovation, customer experience insights and best practices for maximizing customer and employee engagement. Verint will be joined by a prestigious group of industry analysts, customers and thought leaders, who will explore how contact center, CX, branch and back-office operations, government and public sector, and marketing and digital professionals are achieving their goals, meeting and exceeding expectations, and excelling in today’s omnichannel sales, service and marketing environments. Find out more by clicking here. Digital Transformation India 2017 May 30; Mumbai, India Also speaking to the topic of “Customer-Obsessed Game Changers” will be Verint’s Anil Chawla, India country manager. During this regional Forrester event, Chawla will serve as a panel presenter at 3:50 pm IST during this one-day digital transformation event focused on “leading the digital enterprise for innovation and growth.” About Verint Systems Inc. Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimization, security intelligence, and fraud, risk and compliance. Today, more than 10,000 organizations in approximately 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com. This press release contains "forward-looking statements," including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs, and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. For a detailed discussion of these risk factors, see our Annual Report on Form 10-K for the fiscal year ended January 31, 2017 and other filings we make with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and, except as required by law, Verint assumes no obligation to update or revise them or to provide reasons why actual results may differ. VERINT, ACTIONABLE INTELLIGENCE, MAKE BIG DATA ACTIONABLE, CUSTOMER-INSPIRED EXCELLENCE, INTELLIGENCE IN ACTION, IMPACT 360, WITNESS, VERINT VERIFIED, KANA, LAGAN, VOVICI, GMT, VICTRIO, AUDIOLOG, CONTACT SOLUTIONS, OPINIONLAB, ADTECH, CUSTOMER ENGAGEMENT SOLUTIONS, CYBER INTELLIGENCE SOLUTIONS, VOICE OF THE CUSTOMER ANALYTICS, NEXTIVA, EDGEVR, RELIANT, VANTAGE, STAR-GATE, ENGAGE, CYBERVISION, FOCALINFO, SUNTECH, and VIGIA are trademarks or registered trademarks of Verint Systems Inc. or its subsidiaries. Other trademarks mentioned are the property of their respective owners.


-- Increased Investment in its Rapidly Growing Orphan Biologic Medicine for Refractory Chronic Gout, KRYSTEXXA® -- -- Raising KRYSTEXXA Peak Annual Net Sales Estimate to More than $400 Million from More than $250 Million -- -- Announces Acquisition of River Vision Development Corp. and Teprotumumab, a Biologic in Late-Stage Development for a Rare Eye Disease -- -- Revising Full-Year 2017 Net Sales Guidance Range to $1.000 Billion to $1.035 Billion and Full-Year 2017 Adjusted EBITDA Guidance Range to $315 Million to $350 Million; Reflects Revisions to the Primary Care Business Unit Assumptions, Increased Investment in KRYSTEXXA and R&D Investment in Teprotumumab -- -- Announces Board of Directors’ Authorization of Share Repurchase Program for Approximately 10 Percent of Shares Outstanding -- DUBLIN, Ireland, May 08, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first-quarter 2017 financial results today and revised its full-year 2017 net sales and adjusted EBITDA guidance. “We generated strong first-quarter performance in our orphan and rheumatology business units, with KRYSTEXXA and RAVICTI achieving record net sales; however, our primary care business unit performed well below our expectations,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.  “The lower primary care business unit results were related to the implementation of the contracting model with pharmacy benefit managers, which has not performed in accordance with our expectations.  While we are proactively addressing this underperformance, with greater visibility into the impact of this transition, we are revising our full-year 2017 net sales and adjusted EBITDA guidance.” Mr. Walbert added, “We have transformed Horizon Pharma into a company focused on rare disease medicines and we are significantly increasing our investment in one of our key growth drivers, KRYSTEXXA, which we now believe can exceed $400 million in peak annual sales.  That investment is supported by our continued expectation of strong cash-flow generation for the year, which also allows us to continue to seek attractive acquisitions, such as River Vision, which we announced today.  These actions, in addition to our newly authorized share repurchase program, reflect our confidence in the long-term value of our Company.” • Orphan Business Unit:  First-quarter orphan business unit net sales increased 70 percent compared to the first quarter of 2016. RAVICTI net sales in the first quarter of 2017 were $43.9 million, an increase of 18 percent compared to the first quarter of 2016.  The Company expects RAVICTI to be launched in Europe later in 2017 in partnership with Swedish Orphan Biovitrum AB (SOBI). PROCYSBI net sales in the first quarter of 2017 were $34.3 million, up 25 percent compared to Raptor’s pre-acquisition net sales of $27.5 million in the first quarter of 2016, driven by continued strong patient demand from both patients converting from older-generation therapy as well as treatment-naïve patients. ACTIMMUNE net sales in the first quarter of 2017 were $26.2 million, an increase of 3 percent versus the first quarter of 2016.  The Company has evolved its strategy to establish the role of ACTIMMUNE in a broader range of chronic granulomatous disease patients and ACTIMMUNE remains on track to return to growth for the full-year 2017. The Company continues to make progress in the Phase 1 dose escalation trial evaluating ACTIMMUNE as part of a combination therapy in solid tumors for certain cancers.  In February, preliminary data presented at the American Society of Clinical Oncology Clinical Immuno-Oncology Symposium conference showed that combination therapy of ACTIMMUNE with nivolumab, a PD-1 inhibitor, was safe and well-tolerated in the first two cohorts.  The data also showed statistically significant activation of certain monocytes, or white blood cells in peripheral blood, which demonstrates that ACTIMMUNE is having the desired effect of stimulating immune cells.  These are early results, and the third cohort of patients is still under study.  In the first quarter of 2017, a fourth cohort was added to the study to more fully assess dose response.  In addition, a number of academic and clinical institutions have expressed interest in studying ACTIMMUNE as combination therapy in certain cancers, including the National Cancer Institute, which plans to initiate a study later this year to treat patients with Cutaneous T-Cell Lymphoma (CTCL) with ACTIMMUNE and pembrolizumab, a PD-1 inhibitor. The acquisition of River Vision provides the Company with teprotumumab, a fully human monoclonal antibody that targets Insulin-like Growth Factor-1 receptor (IGF-1R).  Teprotumumab is in late-stage development for TED, and has received Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.  On May 4, 2017, The New England Journal of Medicine published teprotumumab Phase 2 study results that demonstrate significant clinical efficacy in TED.  Teprotumumab was also safe and well tolerated.  The Company expects to begin a Phase 3 pivotal program of teprotumumab in TED in the second half of 2017. • Rheumatology Business Unit:  KRYSTEXXA net sales in the first quarter of 2017 were $31.6 million, an increase of 96 percent compared to the first quarter of 2016.  Since acquiring the medicine in January of 2016, the Company’s improved commercial strategy and additional investment in commercial, education and outreach efforts has rapidly accelerated KRYSTEXXA net sales. Based on the continued increase in uptake of KRYSTEXXA and the clear unmet need that exists for thousands of refractory chronic gout sufferers, the Company will significantly increase its infrastructure and investment in the medicine.  Beginning in the second quarter and continuing through the second half of 2017, the Company will expand its commercial organization to nearly 200 employees from more than 100.  With the additional resources, the Company expects to expand its reach to physicians and increase awareness of refractory chronic gout among physicians and patients.  As a result, the Company now expects KRYSTEXXA annual peak net sales of more than $400 million versus the previous estimate of more than $250 million. • Primary Care Business Unit:  Total net sales for the primary care business unit were $65.6 million in the first quarter of 2017.  Net sales of PENNSAID 2%, DUEXIS and VIMOVO in the first quarter of 2017 were $41.6 million, $17.7 million and $4.9 million, respectively. During the second half of 2016, the Company entered into rebate agreements with pharmacy benefit managers (PBMs) in an effort to secure broader inclusion of its primary care medicines on healthcare plan formularies.  This transition to PBM rebate agreements, most of which became effective January 1, 2017, was a change to the commercial model of the Company’s primary care business unit, and following this transition, first-quarter 2017 primary care business unit net sales were lower than the Company’s expectations. Total prescription volumes for DUEXIS, VIMOVO and PENNSAID 2% were approximately in line with the Company’s expectations in the first quarter of 2017.  However, the average net realized price (ANRP) was significantly below expectations due to higher patient assistance costs and higher PBM rebate levels than anticipated.  This was a function of lower-than-anticipated adoption rates of the Company’s primary care medicines onto certain healthcare plan formularies (custom clients), resulting in higher patient assistance costs to the Company, as well as fact that PBM plans that covered the Company’s primary care medicines are primarily plans that require a higher rebate (PBM-chosen formulary clients), resulting in higher rebate costs.  To a lesser extent, the lower ANRP in the quarter was also due to a higher rate of managed care control in the Company’s non-contracted business, reflecting an industry-wide trend. PBM clients broadly fall into two categories, clients that follow a PBM-chosen formulary and clients where the PBM works on their behalf to provide customized formularies (custom clients).  Rebate amounts paid to the PBMs for custom clients are typically lower than rebate amounts paid to the PBM for PBM-chosen formulary clients. When the Company established its financial guidance for full-year 2017, the Company estimated the adoption trajectory and mix of PBM clients that the change to its commercial model would generate.  This took into account input from the PBMs.  The Company did not have full visibility into the actual PBM client mix and the magnitude of the difference compared to its assumptions until it received detailed PBM invoices in late April and early May. While the Company continues to work to drive adoption of its medicines with custom clients, it now expects a much lower level of adoption of custom client plans in 2017.  Compared to its previous financial guidance, the Company has incorporated a higher level of rebates, a higher level of patient assistance costs and a lower level of total prescription volume into its full-year 2017 primary care business unit net sales forecast.  It is also reducing certain primary care business unit operating costs as well as other company costs to align its cost structure with revised net sales expectations.  As a result, the Company has lowered its full-year 2017 net sales and adjusted EBITDA guidance. First-Quarter 2017 Financial Results Note:  For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release. For the full-year 2017, the Company expects continued strong net sales growth for both its orphan and rheumatology businesses, driven primarily by strong patient growth in KRYSTEXXA, RAVICTI and PROCYSBI.  In its primary care business unit, the Company is assuming net sales of more than $300 million. As a result of these expectations, the Company revised its full-year 2017 net sales guidance range to $1.000 billion to $1.035 billion from $1.240 billion to $1.290 billion.  The Company revised its full-year 2017 adjusted EBITDA guidance to $315 million to $350 million from $525 million to $575 million, which assumes the lower net sales range and accounts for cost reductions, primarily in its primary care business, and a reinvestment of a portion of these reductions in KRYSTEXXA to maximize its long-term potential.  It also reflects an approximate $20 million increase in operating expenses, primarily in R&D, for full-year 2017 related to teprotumumab.  The Company is raising its estimate of peak annual net sales for KRYSTEXXA to $400 million from $250 million. At 7:30 a.m. EST / 12:30 p.m. IST today, the Company will host a live conference call and webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com.  Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the conference call will be available approximately two hours after the call and accessible through one of the following telephone numbers, using the passcode below: About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page. Note Regarding Use of Non-GAAP Financial Measures EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon Pharma as non-GAAP financial measures.  Horizon Pharma provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP tax rate and non-GAAP operating cash flow, each of which include adjustments to GAAP figures.  These non-GAAP measures are intended to provide additional information on Horizon Pharma’s performance, operations, expenses, profitability and cash flows.  Adjustments to Horizon Pharma's GAAP figures as well as EBITDA exclude acquisition-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, an upfront fee for a license of a patent, a litigation settlement, loss on debt extinguishment and loss on sale of long-term investments, costs of debt refinancing, drug manufacturing harmonization costs, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, intangible and other non-current asset impairment charges, and other non-cash adjustments.  Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred.  Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures.  Horizon Pharma believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon Pharma's financial and operating performance.  The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2017 financial results and trends and to facilitate comparisons between periods and with respect to projected information.  In addition, these non-GAAP financial measures are among the indicators Horizon Pharma's management uses for planning and forecasting purposes and measuring the Company's performance.  For example, adjusted EBITDA is used by Horizon Pharma as one measure of management performance under certain incentive compensation arrangements.  These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.  Horizon Pharma has not provided a reconciliation of its full-year 2017 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon Pharma's stock price, the variability associated with the size or timing of acquisitions and other factors.  These components of net income (loss) could significantly impact Horizon Pharma’s actual net income (loss). Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's full-year 2017 net sales and adjusted EBITDA guidance, expected peak annual sales of KRYSEXXA, growth of 2017 ACTIMMUNE net sales and 2017 nets sales of Horizon Pharma’s primary care business unit medicines, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, including the planned Phase 3 pivotal clinical trial of teprotumumab and anticipated additional clinical trials of ACTIMMUNE in cancer indications, the timing and potential benefits of Horizon Pharma’s acquisition of River Vision, planned reductions in the Company’s primary care operating expenses and increases in R&D investment and KRYSTEXXA commercialization spending, the expected future impact of Horizon Pharma’s primary care business unit PBM contracting commercial model, the expected launch of RAVICTI in Europe, potential market opportunity for Horizon Pharma’s medicines in approved and potential additional indications, potential growth of Horizon Pharma’s medicines and business and other statements that are not historical facts.  These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon Pharma’s actual future financial and operating results may differ from its expectations or goals; Horizon Pharma’s ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers and risks relating to Horizon Pharma’s ability to successfully implement its business strategies; whether Horizon Pharma is able to realize expected benefits from arrangements with PBMs; risks related to acquisition integration and achieving projected benefits; risks associated with clinical development and regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC.  Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.


News Article | March 2, 2017
Site: www.marketwired.com

Panel with infoedge, Logicserve Digital, Yeahmobi and Nykaa.com to Provide Insights on the Top Challenges of the Performance Marketing Revolution Including Transparency, Quality and Conversion Ratios NEWPORT BEACH, CA--(Marketwired - Mar 2, 2017) - Accelerize ( : ACLZ) ( : ACLZ) and its digital marketing software division CAKE today announced that its President, Santi Pierini, will join leading digital marketers on an ad:tech New Delhi panel titled "The Top Challenges of The Performance Marketing Revolution." The session will provide insights into the obstacles performance marketers must overcome to maximize return on adspend, enhance market positioning, better segment customer profiling and build out robust optimization strategies. Participants include Sumeet Singh, Chief Marketing Officer of infoedge; Prasad Shejale, Co-founder and CEO of Logicserve Digital; Hand Sun, CEO of India for Yeahmobi and Hitesh Malhotra, Chief Marketing Officer of Nykaa.com. The ad:tech New Delhi session takes place Friday, March 10 at 12:15 p.m. IST in the Maple ballroom at the Leela Ambience Gurgaon. ad:tech New Delhi, held March 9-10 at the Leela Ambience Gurgaon, brings together more than 6,500 digital marketers from over 31 countries with the goal of connecting modern marketers with suppliers, networks, digital strategies and innovative trends and technology. Featuring a two-day line up of insightful sessions and an exhibit hall, ad:tech New Delhi seeks to uncover the emerging digital and mobile markets. During "The Top Challenges of The Performance Marketing Revolution" session, panelists will explore the shift from traditional performance marketing and challenges associated with single channel, silo-based reporting, to a new standard that incorporates multi-channel campaigns with robust attribution modeling, customer profiling and greater optimization strategies. The panel will also: According to a report from the National Association of Software and Services Companies (NASSCOM) and Akamai Technologies, India is projected to have 730 million internet users by 2020. India's user base is the second largest after China's and will continue to remain the fastest growing market. "Performance marketing has evolved beyond a single channel to now include innovative technology that helps digital marketers understand the true return on their ad spend," said Santi Pierini, President at CAKE. "With the right infrastructure in place, modern marketers have expanded their digital strategies to include a multi-channel approach where data and consumer behaviors drive ad spend and attribution modeling creates greater optimization strategies." CAKE will exhibit at booth #70 and #71 at the Leela Ambience Gurgaon on Thursday, March 9 from 10 a.m. to 6 p.m. IST and Friday, March 10 from 10 a.m. IST to 5:30 p.m. IST. CAKE, a division of Accelerize Inc., provides a proprietary cloud-based solution to track, attribute and optimize the performance of digital marketing return on ad spend, in real-time. Bringing clarity to multi-channel marketing campaigns, we empower advertisers, agencies, publishers and networks from more than 40 countries worldwide with the insight to make intelligent marketing decisions. CAKE by Accelerize is headquartered in Newport Beach, Calif. with operations in London and New Delhi. For more information, visit www.getCAKE.com. Accelerize Inc. ( : ACLZ) ( : ACLZ) offers marketing technology solutions that revolutionize the way advertisers leverage their digital advertising data. For more information, visit www.accelerize.com. This press release may contain forward-looking statements from Accelerize Inc. within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when Accelerize describes the growth of internet users in India, and uses other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, Accelerize is using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Accelerize only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products and services; unforeseen market and technological difficulties may develop with our products and services; inability to timely develop and introduce new technologies, products and applications; or, loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Accelerize to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Accelerize undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Accelerize, reference is made to Accelerize's reports filed from time to time with the Securities and Exchange Commission.


PETAH TIKVA, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the fourth quarter and full year ended December 31, 2016. “I am pleased to report Gilat's positive results in the fourth quarter and for full year 2016,” said Yona Ovadia, CEO of Gilat. "We made progress in our broadband and In-Flight Connectivity (IFC) growth engines and continued to invest in our technology leadership, while keeping profitability improvement as a high management priority. As a result, we achieved a profitable fourth quarter along with full-year Adjusted EBITDA within the range of our 2016 management objectives, despite ongoing headwinds in Latin America and a slowdown at the end of the year in our Peru project. “In Q4, as part of our broadband strategy, we are pleased to have made progress also in affordable broadband to consumers, as we recently won Tricolor TV, the largest DTH (Direct-to-Home) provider in Russia, who plans to include our unique world’s first all outdoor Scorpio VSAT. In mobility, our technology continues to be chosen for In-Flight Connectivity (IFC) as reflected in our strategic partnership with Air Esurfing, an Air Media wholly owned subsidiary in China, to deliver broadband connectivity to airlines throughout China. We were also awarded a joint R&D project with Airbus for the development of a fully integrated Electronically Steerable Antenna (ESA) aero terminal based on our leading phased array technology. “Our management objectives for 2017 are a continuation and acceleration of our achievements in 2016. Our objectives are for revenues between $280 to $300 million, GAAP operating income between $4 and $8 million and Adjusted EBITDA of between $20 and $24 million, which reflect a high management priority on profitability, in parallel with continued focus on our broadband and mobility growth engines, via maintaining product innovation and leadership.” Conference Call and Webcast Details: Gilat management will host a conference call today, February 14, at 14:30 GMT / 09:30 AM EST / 16:30 IST to discuss the fourth quarter and full year results. International participants are invited to access the call at (972) 3-918-0610, and US-based participants are invited to access the call by dialing 1-888-407-2553. A simultaneous Webcast of the conference call will be available on the Gilat website at www.gilat.com and through this link: http://www.veidan-stream.com/?con=Gilat_Satellite_Networks_Q4_2016_Results The webcast will also be archived for a period of 30 days on the Company’s website and through the link above. Conference Call Replay A replay of the conference call will be available beginning approximately 17:00 GMT/ 12:00 PM EST/ 19:00 IST today, until 17:00 GMT/ 12:00 PM EST/ 19:00 IST on February 17, 2017. International participants are invited to access the replay of the call at (972) 3-925-5901, and US-based participants are invited to access the call by dialing 1-888-782-4291. A replay of the call may also be accessed as a webcast via Gilat’s website at www.gilat.com and will be archived for 30 days. Non-GAAP Measures The attached summary unaudited financial statements were prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). To supplement the consolidated financial statements presented in accordance with GAAP, the Company presents Non-GAAP presentations of net income, operating income, Adjusted EBITDA and earnings per share. The adjustments to the company’s GAAP results are made with the intent of providing both management and investors a more complete understanding of the company’s underlying operational results, trends and performance. Gilat is presenting Adjusted EBITDA (operating income before depreciation, amortization, non-cash stock option expenses and other costs related to acquisition transactions, restructuring cost, goodwill impairment, impairment of long lived assets and trade secrets litigation expenses) due to a significant increase in litigation expense relating to an ongoing trade secrets litigation in the U.S. against former employees, which commenced in 2015. Adjusted EBITDA is presented to compare the company’s performance to that of prior periods and evaluate the company’s financial and operating results on a consistent basis from period to period. The company also believes this measure, when viewed in combination with the company’s financial results prepared in accordance with GAAP, provides useful information to investors to evaluate ongoing operating results and trends. Adjusted EBITDA, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company's Operating income and Adjusted EBITDA is presented in the attached summary financial statements. Non-GAAP presentations of net income, operating income, Adjusted EBITDA and earnings per share should not be considered in isolation or as a substitute for any of the consolidated statements of operations prepared in accordance with GAAP, or as an indication of Gilat’s operating performance or liquidity. About Gilat Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT) is a leading global provider of satellite-based broadband communications. With 30 years of experience, we design and manufacture cutting-edge ground segment equipment, and provide comprehensive solutions and end-to-end services, powered by our innovative technology. Delivering high value competitive solutions, our portfolio comprises of a cloud based VSAT network platform, high-speed modems, high performance on-the-move antennas and high efficiency, high power Solid State Amplifiers (SSPA) and Block Upconverters (BUC). Gilat’s comprehensive solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense and public safety, all while meeting the most stringent service level requirements.  Gilat controlling shareholders are the FIMI Private Equity Funds. For more information, please visit: www.gilat.com Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, inability to maintain market acceptance to Gilat's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology and risks associated with Gilat's international operations and its location in Israel. We undertake no obligation to update or revise any forward-looking statements for any reason. For additional information regarding these and other risks and uncertainties associated with Gilat's business, reference is made to Gilat's reports filed from time to time with the Securities and Exchange Commission.


News Article | February 15, 2017
Site: www.prweb.com

South Florida entrepreneur & spray tan expert Melissa Weinberg continues to successfully expand her brand in the Sunless tanning industry. Both of her brands Perfect Glow Sunless™ and Melissa Weinberg Tanning & Beauty ® have quickly become leaders for their unmatched quality and customer service. She is the top South Florida spray tan expert since 2009 providing custom airbrush tanning in the Palm Beach area. Weinberg had researched for years to successfully develop her professional Sunless beauty line which launched in the beauty industry in 2014. Since then Perfect Glow Sunless™ has quickly risen to great success to become one of the top leading companies in Sunless. Used by salons and spas worldwide, her paraben free and vegan proprietary spray tan solutions continue to receive 5 star accolades. All products are formulated with organic & natural based ingredients sans the harsh ingredients & typical spray tan odor that is found in many other products to produce a flawless and superior spray tanning experience. Salon and spa owners worldwide have turned to the outstanding quality of Perfect Glow Sunless to provide their clients with the best airbrush tan color. Her successful entrepreneurial journey was recently highlighted in Learnvest.com and featured in Forbes.com and Money magazine. (Turning a side gig into a 9-5 business). Perfect Glow Sunless™ was voted as a top 3 finalist for favorite spray tan solution by IST magazine readers. Her luxury brand beat out most other longer established & well-known beauty brands in the industry. She is the only newer company to receive this honor. Both product lines are proudly featured at the luxurious Nspa Delray Beach Marriott, an Opal resort property. Her retail line (Melissa Weinberg tanning & Beauty ®) products continue to earn top reviews by both consumers and beauty bloggers and are now also available on Amazon for retail shoppers. This luxury line of self-tanning and body care products last longer and are superior color compared to others on the market. Formulated with top shelf ingredients such as Moroccan Argan Oil, Coconut Oil, Hemp Seed oil & Marine extracts to name a few & without the nasty chemicals used in other products in the market, such as parabens, formaldehyde, sulfates, mineral oils, glycols, glutens or petrochemicals. They are also certified vegan & Cruelty free by PETA as part of their “Beauty Without Bunnies Program”. Now consumers can get a healthier, top quality salon grade tan in the comfort of their own home. Weinberg was invited as to be a guest speaker at the annual ASTP Sunless Summit convention held in Las Vegas Nevada. Her Perfect Glow Sunless™ Spray Tan Academy has expanded to include instructors in various states. The academy offers various spray tan training and consulting courses for individuals looking to start a spray tan business or for beauty professionals looking to add it to their menu of services. Her spray tan classes have earned top reviews in the industry. Weinberg published her first successful eBook “Ready..Set..Glow” which features marketing tips for beauty professionals. Melissa is also is an avid blogger providing the beauty industry with top sunless tips. Since facing skin cancer, Melissa has become a strong believer in well-being and an advocate for health. Melissa is passionate about offering the world a luxurious beauty product that is safe to use and a product that will offer that “perfect glow” without the perils of natural sun bathing or the hassles of mainstream tanning products. Her beauty brands have provided salon owners & retail consumers worldwide with the highest quality of sunless tanning solutions and aftercare products, earning rave reviews in the process. The company's mission is to provide top quality products, consumer education and excellent customer service. Ms. Weinberg also provides sunless education, training and mentoring to industry professionals worldwide. Retail consumers wishing to find out more about Melissa Weinberg Tanning & Beauty ® and its products can discover more at the company website, located at https://mwmelissaweinberg.com. Salon owners can visit the professional division Perfect Glow Sunless™ website, found at https://perfectglowsunless.com For more information on the Spray Tan Academy please visit https://learntoairbrushtan.com


News Article | February 16, 2017
Site: phys.org

Bright-field images of a zebrafish embryo at sequential stages from the beginning to the end of doming 90 minutes later. Credit: IST The little striped zebrafish starts out as single big cell sitting on top of the yolk. During the next 3 days, cells divide and tissues move to give the fish its final shape. But how do tissues coordinate their often-complicated movements? The physical basis of tissue coordination in early zebrafish development is subject of a study by Carl-Philipp Heisenberg, Professor at the Institute of Science and Technology Austria (IST Austria) and his group, including first author and postdoc Hitoshi Morita, and colleagues at The Francis Crick Institute in London and the Max-Planck-Institute for the Physics of Complex Systems in Dresden. Until now, little has been known about how tissues coordinate their movement both temporally and spatially during development. In the study, published today in Developmental Cell, Heisenberg and co-authors investigated how tissues coordinate their movements and how the forces required for tissue movements are generated. In the paper, they show that cells at the surface are crucial for coordination. Carl-Philipp Heisenberg explains: "A reduction of surface tension by cells on the surface of the embryo is the key process that coordinates tissue movements at this timepoint." Tissue spreading is a key process both in development and disease, for example in wound healing. For a tissue, especially a complex tissue with several layers, to spread, it needs to simultaneously thin and expand. One example of such spreading is the so-called doming in the zebrafish embryo. During doming, the blastoderm, a tissue composed of surface epithelial cells and inner mesenchymal cells, thins and spreads over the yolk cell. Doming involves two tissue movements: the epithelial cell layer at the surface expands, and inner cells undergo intercalations thereby thinning and spreading the inner cell mass. In the present study, Heisenberg and his colleague asked how the two tissue movements - surface cell expansion and inner cell intercalation - coordinate their movements during blastoderm spreading. Combining theory and experiments, they show that surface cells, by undergoing active expansion, reduce the surface tension of the blastoderm. Strikingly, this loosening at the blastoderm surface not only triggers surface cell layer expansion, but also induces inner cell intercalation leading to inner cell layer thinning and spreading. Thus, the reduction in blastoderm surface tension represents the key process coordinating surface cell layer expansion with inner cell layer thinning and spreading during doming. First author Hitoshi Morita explains the significance of this study for understanding tissue spreading: "We have unravelled the force-generating processes that drive doming. Our study shows that by reducing its surface tension, the layer of epithelial cells simultaneously drives expansion and thinning of the blastoderm, and so coordinates these two processes. Coordinated tissue spreading is a universal mechanism by which embryos take shape. Understanding the force-generating mechanism is central for understanding the physical basis of embryo development. We have uncovered the key role surface cells play in this process." Explore further: Healing powers: Team detects mechanism in cell division relevant for closing wounds


-- Fourth-Quarter 2016 Net Sales of $310.3 Million; Up 27 Percent -- -- Fourth-Quarter 2016 Net Loss of $130.5 Million(1); Adjusted EBITDA of $136.4 Million -- -- Full-Year 2016 Operating Cash Flow of $369.5 Million; Full-Year 2016 Non-GAAP Operating Cash Flow of $452.9 Million; Year-End 2016 Cash Balance of $509.1 Million -- -- Full-Year 2017 Net Sales Guidance of $1.24 Billion to $1.29 Billion; Full-Year 2017 Adjusted EBITDA Guidance of $525 Million to $575 Million -- DUBLIN, Ireland, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its fourth-quarter and full-year 2016 financial results today and provided its full-year 2017 net sales and adjusted EBITDA guidance. “We delivered a strong fourth quarter and another exceptional year of performance driven by continued commercial execution and the completion of two transformative acquisitions that bolster our rapidly expanding rare disease business,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.  “Our performance and continued strategic acquisitions have strengthened and diversified the Company and positioned us well to deliver on our growth objectives over the long term.” (1)  The fourth-quarter and full-year 2016 net losses were primarily impacted by the impairment of in-process research and development and other wind- down costs and charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia and acquisition-related costs primarily related to the acquisition of Raptor Pharmaceutical Corp. (2)  On Sept. 26, 2016, Horizon Pharma agreed to pay Express Scripts $65 million as part of a litigation settlement, which was recorded as a one-time reduction to GAAP net sales for the three months ended Sept. 30, 2016, in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  The exclusion of the $65 million settlement from GAAP net sales is the only adjustment reflected in year-to-date 2016 non-GAAP adjusted net sales. Fourth-Quarter 2016 Financial Results Note:  For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release. At 8 a.m. EST / 1 p.m. IST today, the Company will host a live conference call and webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com.  Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the conference call will be available approximately two hours after the call and accessible through one of the following telephone numbers, using the passcode below: About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page. Note Regarding Use of Non-GAAP Financial Measures EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon Pharma as non-GAAP financial measures.  Horizon Pharma provides certain other financial measures such as non-GAAP adjusted net sales and net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP tax rate, non-GAAP operating cash flow and PROCYSBI and QUINSAIR net sales on a combined and adjusted basis, each of which include adjustments to GAAP figures.  These non-GAAP measures are intended to provide additional information on Horizon Pharma’s performance, operations, expenses, profitability and cash flows.  Adjustments to Horizon Pharma's GAAP figures as well as EBITDA exclude acquisition-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, an upfront fee for a license of a patent, a litigation settlement, loss on debt extinguishment and loss on sale of long-term investments, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, intangible and other non-current asset impairment charges, and other non-cash adjustments.  Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred.  Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures.  Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial and operating performance.  The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2017 financial results and trends and to facilitate comparisons between periods and with respect to projected information.  In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance.  For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements.  These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.  Horizon Pharma has not provided a reconciliation of its full-year or quarterly 2017 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon Pharma's stock price, the variability associated with the size or timing of acquisitions and other factors.  These components of net income (loss) could significantly impact Horizon Pharma’s actual net income (loss). Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to Horizon Pharma's full-year and quarterly 2017 net sales and adjusted EBITDA guidance, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, the expected launch of RAVICTI in Europe, anticipated additional clinical trials of ACTIMMUNE in cancer indications, potential market opportunity for Horizon Pharma’s medicines in approved and potential additional indications, potential growth of Horizon Pharma’s medicines and business and other statements that are not historical facts.  These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon Pharma’s ability to grow net sales from existing products; the availability of coverage and adequate reimbursement and pricing from government and third-party payers and risks relating to the success of Horizon Pharma’s business strategies; whether Horizon Pharma is unable to enter into additional business arrangements with pharmacy benefit managers and payers on favorable terms or at all or unable to realize the expected benefits from such arrangements; risks related to acquisition integration and achieving projected cost savings and benefits; risks associated with clinical development and regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon Pharma operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's filings and reports with the SEC.  Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information. The Company acquired Raptor Pharmaceutical Corp. on October 25, 2016, including PROCYSBI and QUINSAIR.  PROCYSBI and QUINSAIR net sales for the partial fourth quarter of 2016 were $25.3 million and $1.0 million, respectively.  The following tables reflect sales for full-year 2015, first, second and third quarter under Raptor Pharmaceutical Corp. ownership and partial fourth-quarter 2016 net sales of Raptor and Horizon on a combined basis. (1) Expenses, including legal and consulting fees, incurred in connection with the Company’s acquisitions of Vidara Therapeutics International Public Limited Company (“Vidara”), Hyperion Therapeutics, Inc. (“Hyperion”), Crealta Holdings LLC (“Crealta”), Raptor Pharmaceutical Corp. (“Raptor”), its agreement to acquire the worldwide rights to interferon gamma-1b and its withdrawn offer to acquire Depomed Inc. have been excluded. (2) Intangible amortization expenses are associated with the Company’s intellectual property rights, developed technology and customer relationships of ACTIMMUNE, BUPHENYL, KRYSTEXXA, LODOTRA, MIGERGOT, PENNSAID 2%, PROCYSBI, RAVICTI, RAYOS and VIMOVO. (3) Represents amortization of debt discount and deferred financing costs associated with the Company's debt. (4) Represents accretion expense associated with the ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, RAVICTI and VIMOVO royalties for the three and twelve months ended December 31, 2016, and represents accretion expense associated with the ACTIMMUNE, BUPHENYL, RAVICTI and VIMOVO royalties for the three and twelve months ended December 31, 2015. (5) In connection with the Crealta acquisition, the KRYSTEXXA and MIGERGOT inventory was stepped up in value by $144,289 and during the three months ended December 31, 2016, the Company recognized in cost of goods sold, $20,889 for step-up inventory costs related to KRYSTEXXA and MIGERGOT inventory sold.  During the twelve months ended December 31, 2016, the Company recognized in cost of goods sold, $48,758 for step-up inventory costs related to KRYSTEXXA and MIGERGOT inventory sold. In connection with the Raptor acquisition, the PROCYSBI and QUINSAIR inventory was stepped up in value by $66,950 and during the three months ended December 31, 2016, the Company recognized in cost of goods sold $22,379 of step-up inventory costs related to PROCYSBI and QUINSAIR inventory sold. In connection with the Hyperion acquisition, the BUPHENYL and RAVICTI inventory was stepped up in value by $8,682 and during the three months and twelve months ended December 31, 2015, the Company recognized in cost of goods sold $860 and $8,341, respectively, of step-up inventory costs related to BUPHENYL and RAVICTI inventory sold.  In connection with the Vidara acquisition, the ACTIMMUNE inventory was stepped up in value by $14,218 and during the first quarter of 2015, the Company recognized in cost of goods sold the remaining $3,154 of step-up inventory costs related to ACTIMMUNE. (6) At the time of the Company's acquisition of the rights to ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, RAVICTI and VIMOVO, the Company estimated the fair value of contingent royalties payable to third parties using an income approach under the discounted cash flow method, which included revenue projections and other assumptions the Company made to determine the fair value.  If the Company significantly over-performs or underperforms against its original revenue projections or it becomes necessary to make changes to assumptions as a result of a triggering event, the Company is required to reassess the fair value of the contingent royalties payable.  Any subsequent adjustment to fair value is recorded in the period such adjustment is made as either an increase or decrease to royalties payable, with a corresponding increase or decrease in cost of goods sold, in accordance with established accounting policies.  During the three and twelve months ended December 31, 2016, the Company recorded a net charge of $386, to cost of goods sold to adjust the amount of the contingent royalty liabilities relating to ACTIMMUNE, KRYSTEXXA, RAVICTI and VIMOVO.  During the three and twelve months ended December 31, 2015, the Company recorded a net charge of $6,874 and $21,151, respectively, to cost of goods sold to adjust the amount of the contingent royalty liabilities relating to ACTIMMUNE, RAVICTI and VIMOVO. (7) Represents share-based compensation expense associated with the Company's stock option, restricted stock unit, and performance stock unit grants to its employees and non-employees, its cash-settled long-term incentive program and its employee stock purchase plan. (8) Represents depreciation expense related to the Company’s property, equipment, software and leasehold improvements. (9) Represents a charge for the impairment of in-process R&D related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia.  (10) Represents charges for wind-down costs related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia.  (11) Royalties of $10,434 and $37,593 were incurred during the three and twelve months ended December 31, 2016, respectively, based on the periods’ net sales for ACTIMMUNE, BUPHENYL, KRYSTEXXA, MIGERGOT, PROCYSBI, RAVICTI and VIMOVO.  Royalties of $8,944 and $29,834 were incurred during the three and twelve months ended December 31, 2015, respectively, based on the periods’ net sales for ACTIMMUNE, BUPHENYL, RAVICTI and VIMOVO. (12) Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment. (13) During the three months ended September 30, 2015, the Company purchased 2,250,000 shares of common stock of Depomed, Inc. ("Depomed") representing 3.75 percent of Depomed's then outstanding common stock. The shares were acquired at a cost of $71,813.  During the three months ended December 31, 2015, following the Company's decision to withdraw its offer to acquire Depomed, the Company sold all of its shares in Depomed, receiving sales proceeds of $42,781. Following this sale, the Company recognized a loss of $29,032 in the consolidated statement of comprehensive income (loss). (14) Represents an upfront fee paid for a license of a global patent.  (15) On September 26, 2016, the Company agreed to pay Express Scripts $65 million as part of a litigation settlement, which was recorded as a one-time reduction to GAAP net sales for the twelve months ended December 31, 2016, in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  The exclusion of the $65 million settlement from GAAP net sales is the only adjustment reflected in the non-GAAP adjusted net sales for the twelve months ended December 31, 2016.  (16) During the third quarter of 2016, the Company released a contingent liability of $6.9 million that was recorded as part of acquisition accounting for Crealta.  (17) During the twelve months ended December 31, 2015, the Company recorded a loss on induced debt conversions of $77,624, which represented an early redemption payment of $45,366, the write-down of $21,581 in debt discount and deferred financing costs, $10,005 in additional exchange consideration to debt holders and $672 in expenses incurred in connection with the induced debt conversions.  (18) Other non-GAAP income tax adjustments in the twelve months ended December 31, 2015 of $105,133 related to the release of certain valuation allowances in connection with the Hyperion acquisition.


Ecosmob Shared the Success of Their First Webinar on Go Cashless with Digital Transactions Ecosmob Technologies recently conducted a live webinar on the subject: Go Cashless with Digital Transactions. The spokesperson of the company shared the details of the success of this webinar. Ahmedabad, India, December 28, 2016 --( The webinar was conducted last Thursday, 22nd December, 2016 at 3:00 PM IST. The webinar was designed for the global audience as the digital transactions is the talk of the town in almost each country around the globe. The spokesperson of the company shared, “Along with India, there are many countries which encourage digital transactions. We wanted to share thorough knowledge on this to the global audience. We were specifically targeting the audiences who are owners or in the management team of the company which would like to make digital transactions part of their business. We were very happy to receive an outstanding response by the audience.” “The webinar received 100+ registrations to be part of this webinar. We had limited seats so we couldn’t include each of them. Still, we had 75+ live audiences who attended this webinar from across the world. Our domain experts shared basic to advanced knowledge on the stated topic and also shared some amazing statistics. There was a live question answer round in which we received interesting questions from business people who wanted to make digital transactions part of their business. Each of them was belonging to different industry, including, vocal artist, textile business, real estate broker, etc. After the webinar, we have received a great feedback from the audience,” shared spokesperson of the company. The proposed three possible business models to integrate digital transactions in the business during the webinar are: - IVR Solution - Mobile Application - Web Application The webinar was delivered by: - Krunal Patel, Business Head, Ecosmob Technologies - Sachin Ghulyani, Business Development Manager, Ecosmob Technologies The webinar was moderated by: - Ashvini Vyas, Digital Marketing Manager, Ecosmob Technologies The spokesperson of the company further added, "We are thankful to everyone who participated in the webinar. Our team also worked at their best to give best possible information to our webinar audience. It was a very first webinar conducted by our company and we are amazed with the response we received. "We have made the webinar recording and presentation live for the participants, registrants as well as for other interested people." The webinar resources can be accessed from the below links: YouTube: https://youtu.be/ll1sA4tvj_I Presentation: http://bit.ly/2ihB6ds Ecosmob would be glad to answer any queries. The webinar material is open for public access. If you have any questions, you can directly drop an email at sales@ecosmob.com https://www.ecosmob.com Ahmedabad, India, December 28, 2016 --( PR.com )-- Ecosmob Technologies is a renowned IT company from India, which is known for its client centric approach. The company is also known for the innovations it brings into the industry. The company had conducted a live webinar on the subject of: Go Cashless with Digital Transactions. The spokesperson of the company announced that the webinar was successful and received a very good response from the audience.The webinar was conducted last Thursday, 22nd December, 2016 at 3:00 PM IST. The webinar was designed for the global audience as the digital transactions is the talk of the town in almost each country around the globe. The spokesperson of the company shared, “Along with India, there are many countries which encourage digital transactions. We wanted to share thorough knowledge on this to the global audience. We were specifically targeting the audiences who are owners or in the management team of the company which would like to make digital transactions part of their business. We were very happy to receive an outstanding response by the audience.”“The webinar received 100+ registrations to be part of this webinar. We had limited seats so we couldn’t include each of them. Still, we had 75+ live audiences who attended this webinar from across the world. Our domain experts shared basic to advanced knowledge on the stated topic and also shared some amazing statistics. There was a live question answer round in which we received interesting questions from business people who wanted to make digital transactions part of their business. Each of them was belonging to different industry, including, vocal artist, textile business, real estate broker, etc. After the webinar, we have received a great feedback from the audience,” shared spokesperson of the company.The proposed three possible business models to integrate digital transactions in the business during the webinar are:- IVR Solution- Mobile Application- Web ApplicationThe webinar was delivered by:- Krunal Patel, Business Head, Ecosmob Technologies- Sachin Ghulyani, Business Development Manager, Ecosmob TechnologiesThe webinar was moderated by:- Ashvini Vyas, Digital Marketing Manager, Ecosmob TechnologiesThe spokesperson of the company further added, "We are thankful to everyone who participated in the webinar. Our team also worked at their best to give best possible information to our webinar audience. It was a very first webinar conducted by our company and we are amazed with the response we received."We have made the webinar recording and presentation live for the participants, registrants as well as for other interested people." The webinar resources can be accessed from the below links:YouTube: https://youtu.be/ll1sA4tvj_IPresentation: http://bit.ly/2ihB6dsEcosmob would be glad to answer any queries.The webinar material is open for public access. If you have any questions, you can directly drop an email at sales@ecosmob.comhttps://www.ecosmob.com


News Article | February 16, 2017
Site: www.businesswire.com

CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, reported record revenue for the fourth quarter and full year ended December 31, 2016. As previously announced, the Company received purchase orders for 21 systems in the fourth quarter and ended the year with a backlog of 21 systems, including 18 Mazor X systems, its transformative platform for spine surgeries, which was commercially launched in October. “Our record performance in the fourth quarter and success throughout the year reinforces 2016 as a strategic turning point for the Company,” commented Ori Hadomi, Chief Executive Officer. “We have greatly enhanced our leadership position in the spine market with the implementation of the Medtronic co-marketing and co-promotional agreement and the launch of the transformational Mazor X system. While our systems order growth is impressive, our high utilization rate and recurring revenue growth illustrates the benefits Mazor is bringing to both surgeon and patient. With a strong backlog, we enter 2017 with momentum to continue our growth.” Revenue for the three months ended December 31, 2016 increased 59% to $14.0 million compared to $8.8 million in the year-ago fourth quarter. U.S. revenue increased 88% to $12.6 million compared to $6.7 million in the year-ago fourth quarter, as the Company recognized revenue from 13 Mazor X and two Renaissance systems, compared to ten Renaissance systems in the year-ago fourth quarter. The Company ended the quarter with a backlog of 21 systems; revenue from these systems is expected to be recorded in 2017, generally, when the systems are supplied. International revenue was $1.4 million compared to $2.1 million in the year-ago fourth quarter, as the Company recognized revenue from three Renaissance systems, compared to four Renaissance systems in the year-ago fourth quarter. Recurring revenue from system kit sales, services and other increased 29% to $4.5 million in the fourth quarter of 2016, compared to $3.5 million in the year-ago fourth quarter. The increase is attributed to high utilization rates and increase of the install base. The Company’s gross margin for the three months ended December 31, 2016 was 70.5% compared to 78.0% in the year-ago fourth quarter. The decrease is attributed mainly to discounted price to our distribution partner, Medtronic, and the higher manufacturing costs of the Mazor X, compared to the Renaissance system. Total operating expenses were $14.2 million compared to $9.8 million in the year-ago fourth quarter, primarily reflecting the Company’s increased investments in sales and marketing activities. Operating loss was $4.3 million compared to an operating loss of $2.9 million in the year-ago fourth quarter. Net loss for the fourth quarter of 2016 was $4.3 million, or $0.09 per share, compared to a net loss of $2.9 million, or $0.07 per share, for the year-ago fourth quarter. Cash used in operating activities was $1.9 million compared to $4.3 million used in last year’s fourth quarter. The decrease is mainly due to high collection from customers, offset by higher payments to suppliers. As of December 31, 2016, cash, cash equivalents and investments totaled $61.8 million. The tables below include reconciliation of the Company’s GAAP results to non-GAAP results. The reconciliation relates to non-cash expenses in the amount of $1.1 million with respect to amortization of intangible assets and to share-based expenses recorded in the fourth quarter of 2016. On a non-GAAP basis, the net loss in the fourth quarter of 2016 was $3.1 million, or $0.07 per share, compared to $2.1 million, or $0.05 per share, for the year-ago fourth quarter. For the full year ended December 31, 2016, revenue increased 39% to $36.4 million compared to $26.1 million for the full year ended December 31, 2015. U.S. revenue increased 51% to $30.7 million compared to $20.3 million in the full year ended December 31, 2015, as the Company recognized revenue from 30 systems, compared to 16 systems in the full year ended December 31, 2015. International revenue was $5.7 million compared to $5.8 million in the full year ended December 31, 2015, as the Company recognized revenue from 11 Renaissance systems, compared to eight Renaissance systems in the full year ended December 31, 2015. Recurring revenue totaled $16.8 million compared to $12.7 million for the full year ended December 31, 2015. The growth in recurring revenue is attributed to the increase of the install base of the Company’s Renaissance system in the U.S. and globally. Gross margin for the full year ended December 31, 2016 was 71.6% compared to 77.7% for the full year ended December 31, 2015. The decrease is mainly attributed to the discounted price to our distribution partner, the lower price of Renaissance (effective Q3 2016) and the higher manufacturing costs of the Mazor X, compared to the Renaissance system. Total operating expenses were $45.1 million compared to $35.6 million in the full year ended December 31, 2015, primarily reflecting the Company’s increased investments in sales and marketing activities. Operating loss was $19.0 million compared to an operating loss of $15.3 million in the full year ended December 31, 2015. Net loss for the full year ended December 31, 2016 was $18.7 million, or $0.42 per share, compared to $15.4 million, or $0.36 per share for the full year ended December 31, 2015. Cash used in operating activities was $10.1 million compared to $11.6 million used in the full year ended December 31, 2015. The decrease is mainly due to high collection from customers. The tables below include reconciliation of the Company’s GAAP results to non-GAAP results. The reconciliation relates to non-cash expenses in the amount of $2.6 million with respect to capitalization of research and development costs, amortization of intangible assets and to share-based expenses recorded in 2016. On a non-GAAP basis, the net loss for the full year ended December 31, 2016 was $16.1 million, or $0.36 per share, compared to a net loss of $12.3 million, or $0.29 per share, for the full year ended December 31, 2015. The Company will host a conference call to discuss these results on February 16, 2017 at 8:30am ET (3:30 PM IST). Investors within the United States interested in participating are invited to call 888-312-3052. Participants in Israel can use the toll free dial-in number 1 80 924 5905. All other international participants can use the dial-in number 719-457-2695. A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-866-375-1919 and reference the Replay Access Code: 2887710. All international callers can dial +1 719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’ In addition to disclosing financial results calculated in accordance with generally accepted accounting principles in conformity with International Financial Reporting Standards (GAAP), this press release contains Non-GAAP financial measures for gross profit, operating expenses, operating loss, net loss and basic and diluted earnings per share that exclude the effects of capitalization of research and development costs, non-cash expense of amortization of intangible assets and share-based expenses. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performance that enhances management's and investors' ability to evaluate the Company's net income and earnings per share and to compare them to historical net income and earnings per share. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company’s business internally and therefore decided to make these non-GAAP adjustments available to investors. Mazor Robotics (TASE:MZOR; NASDAQGM:MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance System enables surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the Company’s expectations for 2017, the amount of and timing of recording of additional revenue from backlog, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Loading IST GmbH collaborators
Loading IST GmbH collaborators